
CorMedix Inc (NASDAQ:CRMD - Free Report) - Investment analysts at HC Wainwright issued their FY2027 earnings estimates for CorMedix in a report issued on Monday, June 30th. HC Wainwright analyst B. Folkes expects that the company will earn $1.89 per share for the year. HC Wainwright currently has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for CorMedix's current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for CorMedix's FY2028 earnings at $2.28 EPS.
CRMD has been the subject of several other reports. Leerink Partners assumed coverage on CorMedix in a report on Friday, March 7th. They set an "outperform" rating and a $18.00 price target for the company. D Boral Capital downgraded CorMedix from a "strong-buy" rating to a "hold" rating in a report on Monday, June 30th. Leerink Partnrs raised CorMedix to a "strong-buy" rating in a report on Friday, March 7th. Needham & Company LLC increased their price target on CorMedix from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Tuesday, June 24th. Finally, Wall Street Zen raised CorMedix from a "sell" rating to a "hold" rating in a report on Tuesday, April 1st. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $17.14.
Get Our Latest Stock Analysis on CRMD
CorMedix Stock Up 0.4%
Shares of NASDAQ CRMD traded up $0.05 during mid-day trading on Wednesday, hitting $11.64. 1,079,245 shares of the company were exchanged, compared to its average volume of 1,346,499. The stock has a 50 day simple moving average of $12.52 and a 200-day simple moving average of $10.53. CorMedix has a 1-year low of $3.61 and a 1-year high of $17.43. The firm has a market cap of $789.42 million, a price-to-earnings ratio of 52.91 and a beta of 1.58.
CorMedix (NASDAQ:CRMD - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $0.30 earnings per share for the quarter, topping analysts' consensus estimates of $0.25 by $0.05. The firm had revenue of $39.08 million for the quarter, compared to analyst estimates of $38.90 million. CorMedix had a net margin of 20.81% and a return on equity of 22.57%. During the same period in the prior year, the firm earned ($0.25) earnings per share.
Institutional Inflows and Outflows
Hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp increased its position in shares of CorMedix by 8.2% in the fourth quarter. Bank of New York Mellon Corp now owns 129,695 shares of the company's stock valued at $1,051,000 after buying an additional 9,782 shares in the last quarter. Barclays PLC increased its position in shares of CorMedix by 35.6% in the fourth quarter. Barclays PLC now owns 105,602 shares of the company's stock valued at $855,000 after buying an additional 27,732 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of CorMedix by 40.8% in the fourth quarter. JPMorgan Chase & Co. now owns 273,218 shares of the company's stock valued at $2,213,000 after buying an additional 79,110 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in CorMedix during the 4th quarter worth about $1,085,000. Finally, HighTower Advisors LLC increased its position in CorMedix by 48.9% during the 4th quarter. HighTower Advisors LLC now owns 29,138 shares of the company's stock worth $236,000 after purchasing an additional 9,566 shares in the last quarter. Hedge funds and other institutional investors own 34.18% of the company's stock.
About CorMedix
(
Get Free Report)
CorMedix Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Further Reading
Before you consider CorMedix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CorMedix wasn't on the list.
While CorMedix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.